BIOMAT Database Logo BIOMAT Database Logo

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. 1994

M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114.

Forty-one patients who had failed to respond to 8 weeks of treatment with 20 mg of fluoxetine were randomly assigned to one of three treatments for 4 weeks: 40-60 mg/day of fluoxetine, 20 mg/day of fluoxetine plus 25-50 mg/day of desipramine, and 20 mg/day of fluoxetine plus 300-600 mg/day of lithium. Patients treated with high-dose fluoxetine (N = 15) did significantly better than patients treated with fluoxetine plus lithium (N = 14) and those treated with fluoxetine plus desipramine (N = 12). High-dose fluoxetine was the most effective treatment among partial responders to previous treatment, but high-dose fluoxetine and fluoxetine plus lithium were the most effective treatments among nonresponders.

UI MeSH Term Description Entries
D008094 Lithium An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER. Lithium-7,Lithium 7
D008297 Male Males
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D003891 Desipramine A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors. Desmethylimipramine,Apo-Desipramine,Demethylimipramine,Desipramine Hydrochloride,Norpramin,Novo-Desipramine,Nu-Desipramine,PMS-Desipramine,Pertofran,Pertofrane,Pertrofran,Petylyl,Ratio-Desipramine,Apo Desipramine,Hydrochloride, Desipramine,Novo Desipramine,Nu Desipramine,PMS Desipramine,Ratio Desipramine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study.
April 1999, Journal of clinical psychopharmacology,
M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
[Lithium carbonate augmentation in tricyclic antidepressant-resistant depression].
December 1991, Harefuah,
M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
Concurrent treatment of nonresistant major depression with desipramine and lithium: a double-blind, placebo-controlled study.
February 1997, Journal of clinical psychopharmacology,
M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
A double-blind study of fluoxetine and imipramine in major depression.
January 1989, International clinical psychopharmacology,
M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses.
May 1993, The British journal of psychiatry : the journal of mental science,
M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group.
January 1995, International psychogeriatrics,
M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
April 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,
M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
February 2016, The lancet. Psychiatry,
M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
A randomized double-blind sham-controlled study of transcranial direct current stimulation for treatment-resistant major depression.
January 2012, Frontiers in psychiatry,
M Fava, and J F Rosenbaum, and P J McGrath, and J W Stewart, and J D Amsterdam, and F M Quitkin
A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression.
March 1991, Pharmacopsychiatry,
Copied contents to your clipboard!